Scribe Therapeutics Inc. (SCTX)

NASDAQ: SCTX · Real-Time Price · USD

28.05

-4.95 (-15.00%)

At close: Sep 21, 2026, 4:00 PM EDT

28.90

+0.85 (3.03%)

Pre-market: Sep 22, 2026, 6:00 AM EDT

Scribe Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	33.3	51.17	27.41
Revenue Growth	-	86.68%	-
Cost of Revenue	51.05	60.8	57.08
Gross Profit	-17.75	-9.62	-29.67
Selling, General & Admin	12.96	16.45	13.16
Operating Expenses	12.96	16.45	13.16
Operating Income	-30.71	-26.07	-42.83
Interest Expense	-2.07	-2.39	-2.38
Interest & Investment Income	2.28	3.33	6.15
EBT Excluding Unusual Items	-30.5	-25.14	-39.06
Other Unusual Items	-2.14	1.53	1.5
Pretax Income	-32.64	-23.61	-37.56
Income Tax Expense	-0.33	-1.8	10.23
Net Income	-32.3	-21.81	-47.79
Net Income to Common	-32.3	-21.81	-47.79
Net Income Growth	-	-	-
Shares Outstanding (Basic)	2	2	2
Shares Outstanding (Diluted)	2	2	2
Shares Change	-	1.39%	-
EPS (Basic)	-13.18	-8.98	-19.94
EPS (Diluted)	-13.18	-8.98	-19.94
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-38.22	-46.48	-46.58
Free Cash Flow Per Share	-15.59	-19.14	-19.44
Gross Margin	-53.29%	-18.80%	-108.22%
Operating Margin	-92.20%	-50.94%	-156.24%
Profit Margin	-97.00%	-42.61%	-174.32%
Free Cash Flow Margin	-114.77%	-90.83%	-169.93%
EBITDA	-27.82	-22.99	-39.94
EBITDA Margin	-83.54%	-44.93%	-145.70%
D&A For EBITDA	2.89	3.08	2.89
EBIT	-30.71	-26.07	-42.83
EBIT Margin	-92.20%	-50.94%	-156.24%

SEC Filings: 10-K · 10-Q